Azenta, Inc.

Azenta, Inc. announced the appointment of Erik J. Bello, age 51, as its new Vice President, Chief Accounting Officer, effective August 31, 2026. Mr. Bello previously served as Vice President and Corporate Controller at Onto Innovation Inc. He will receive an annual base salary of $380,000, an $80,000 sign-on bonus, and will be eligible for incentive compensation and long-term incentive awards. Lawrence Lin will continue in his role as Executive Vice President and Chief Financial Officer.

Azenta reported a net loss of $(173.8) million for the nine months ended June 30, 2026, significantly wider than the $(106.6) million loss in the prior year, primarily due to a $149.1 million goodwill and intangible assets impairment. For the third quarter, the company posted a net income of $2.5 million, a substantial improvement from a $(48.0) million loss year-over-year, largely benefiting from income from discontinued operations. The company completed the sale of its B Medical Systems business for $63.0 million on July 1, 2026.

Azenta reported its third quarter fiscal 2026 financial results, with revenue from continuing operations reaching $161 million, an increase of 12% year over year, and organic growth of 9%. The company's Non-GAAP diluted EPS from continuing operations was $0.16, while Adjusted EBITDA from continuing operations grew 6% to $18 million, exceeding expectations despite a challenging market. Azenta also updated its full-year fiscal 2026 guidance, raising the lower end of its reported revenue outlook to $613 million to $618 million and improving its organic revenue growth expectation to flat to up 1%. Additionally, the company repurchased $50.0 million of common stock under its $250 million share repurchase program.

Azenta, Inc. announced the completion of the sale of its B Medical Systems business to Thelema S.à r.l. for a fixed purchase price of $63 million. The transaction, which closed on July 1, 2026, included $28 million in cash and a $35 million secured vendor loan provided by an Azenta subsidiary to Thelema. This divestment aligns with Azenta's strategy to focus on its core life sciences businesses and enhance financial flexibility.

Azenta, Inc. reported a significant net loss of $(160.8) million for the three months ended March 31, 2026, primarily driven by a $149.1 million impairment of goodwill and intangible assets. This compares to a net loss of $(47.7) million in the same period last year. The company also announced a delay in the divestment of its B Medical Systems business, as the buyer has not yet secured the required financing. Total revenue for the quarter saw a modest increase to $144.8 million from $143.3 million year-over-year.

Azenta reported second-quarter fiscal 2026 financial results, with revenue of $145 million, up 1% year-over-year, but organic revenue declined 3%. The company significantly lowered its full-year fiscal 2026 guidance for total reported revenue, organic revenue growth, Adjusted EBITDA margin, and free cash flow, citing execution gaps and a cautious demand environment. Consequently, Azenta extended its long-range plan targets from 2028 to 2029. The sale of B Medical Systems did not close by March 31, 2026, as the buyer has not secured financing.

Azenta, Inc. announced that Ginger Zhou stepped down as President of the Multiomics business, and William "Trey" E. Martin III was appointed as her replacement, effective April 6, 2026. Martin's prior experience as CEO of Maravai LifeSciences Holdings suggests a strategic move to leverage his expertise in the life sciences sector, while Zhou will continue in an advisory role.

Azenta, Inc. announced that Ginger Zhou stepped down as President of the Multiomics business, and William "Trey" E. Martin III was appointed as her replacement, effective April 6, 2026. Zhou will continue in an advisory role through November 2026 with a consulting fee of $103,500, while Martin brings experience as former CEO of Maravai LifeSciences Holdings, Inc., potentially signaling a strategic shift or renewed focus on the Multiomics business.